


Fundamental Forecasts

Enter a ticker or a company name and click on Go.

Company	Ticker	Industry	Quality	PAR	
Stryker	SYK	Medical Supplies (Orthopedic)	76.0	13.2%	
Current Price (12/		\$53.0			
CAPS Rating (Rate	CAPS)	4	****		
		Expected Income Statement			
Current Sales				7,200.0	
Sales Growth Fore	ecast			8.0%	
Net Profit Margin				18.0%	
Projected Shares	Outstanding			390.7	
EPS - Five Year Fo	recast			\$4.87	
Average P/E Ratio				19.6	
Projected Average	Price			\$95.68	
Price Appreciation	(Annualized			12.5%	
Annual Dividend Y	'ield		0.7%		
Projected Annual	Return		13.2%		
		Quality			
Financial Strength	1		99	24.8	
EPS Stability			97	24.2	
Industry Sales Gr	owth Rate		11.4%	8.8	
Industry Net Profi	t Margin		12.3%	18.3	
Calculated Quality	Rating		76.0		
		Fool CAPS			
Total Players 1389 Outperform	ns	30	Underpe	rforms	
All-Stars 492 Outperforms	s (98.8%)	6	Underpe	rforms	
Fundamental Data	updated: 1	1/26/2010			



Orthopaedic Implants (61% of '09 sales), and MedSurg Equipment (39%). Orthopaedic products include hip, knee, trauma, spinal, and craniomaxillofacial implants. MedSurg includes powered instruments, endoscopic systems, other operating room devices, specialty stretchers, and maternity beds. Physical Therapy Services

of '09 sales. '09 depr. rate: 19.6%. Has 18,582 employees. Off. and dir. (incl. Stryker family trust) own 30.7% of stock (3/10 proxy), 3 others aggregrate 15.7%. Chairman, President. & CEO: Stephen MacMillan. Inc.: Ml. Addr.: 2825 Airview Blvd, Kalamazoo, Ml 49002. Telephone: 269-385-2600. Internet: www.stryker.com.

Current Liab. **ANNUAL RATES** Past Est'd '07-'09 Past 5 Yrs. 12.0% to '13-'15 8.5% of change (per sh) 10 Yrs. 16.0% 21.5% 22.0% Sales "Cash Flow" 10.0% 12.5% 17.0% 16.0% 18.5% Earnings Dividends Book Value

4979.3

274.3

1167.3

1462.1

20.5

5851.2

200.2 18.0

1441.0

Current Assets

Accts Payable Debt Due

7543.7

1406.0

247.8

191

Cal-	QU	Full			
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2007	1426	1464	1453	1658	6001
2008	1634	1713	1653	1718	6718
2009		1634	1653	1834	6723
2010	1799	1758	1768	1875	7200
2011	1895	1925	1950	1980	7750
Cal-	E/	ARNINGS F	PER SHAR	ΕA	Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2007	.58	.61	.55	.66	2.40
2008	.70	.73	.66	.69	2.78
2009	.71	.73	.57	.76	2.77
2010	.80	.80	.85	.85	3.30
2011	.87	.90	.92	.96	3.65
Cal-	QUAR	TERLY DIV	IDENDS P	AID B∎	Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2006	.11				.11
2007	.22				.22
2008	.33				.33
2009	.40			.10	.50
2010	.15	.15	.15	.15	

Stryker is actively pursuing acquisitions, once more. The medical device manufacturing giant has signed a definitive agreement to purchase the Neurovascular division of Boston Scientific for \$1.4 billion. The all-cash transaction, with an additional \$100 million pending in potential milestone payments, is expected to close in the fourth quarter. The deal will likely be neutral to slightly accretive to earnings in 2011 and may well add about \$350 million to the top line. Boston Scientific's lineup of neurovascular devices ought to mesh well with Stryker's and widen customer offerings. As per Value Line convention, we will exclude the impact of this transaction in our financial presentation until it has been completed. Also of note, Stryker recently finalized the purchase of privately held Porex Surgical, which will boost head and face reconstructive offerings. And, with SYK sitting on a hearty cash balance, further strategic buys to flesh out portfolio gaps are likely.

Stryker ought to post solid overall results this year. Although sales fell short of our estimate in the September quarter, the top line will likely finish the year with

a healthy 7% advance, thanks to an improving economy, which, in turn, is boosting elective surgeries. Too, the Capital Equipment division, MedSurg, continues to post sales gains, owing to the loosening of hospital budgets and the inevitable need to update equipment. The bottom line is poised for a sharp recovery, with product and expense-reduction measures providing a close-to-20% lift this year. Too, a \$750 million stock-buyback program should lend support, as well.

These shares will likely

appeal to patient accounts. Although SYK stock has climbed about 10% in price since our August review, the current entry point still offers investors wide appreciation potential over the 3- to 5-year horizon. Furthermore, our 2013-2015 share-net estimates may prove conservative, thanks to several acquisitions coming under the Stryker umbrella in short order. What's more, the company will likely continue to add to its offerings through further business combinations. For now, this selection is ranked as an average performer for year-ahead returns.

Mary Beth Wiedenkeller November 26, 2010

(A) Based on average shares through '96; diluted thereafter. Excludes extraordinary gains of \$0.03 in 1996. Excludes nonrecurring losses

\$0.03; '04, \$0.29; '05, \$0.11; '06, 13¢; 07, 4¢; 9/30/10: \$1604.5 million, \$4.04/share. **(D)** In '08, 5¢. Next earnings rpt. due late Januyary. **(B)** Dividends paid early January, April, July, and October. (C) Includes intangibles. At

Company's Financial Strength Stock's Price Stability A++ 90 Price Growth Persistence 75 **Earnings Predictability** 100

STRYKER CORP (SYK)


Stock Prices

Current Price = \$53.08 Exchange: NYSE 52 Week Range = \$42.74 to \$59.72

Industry:

Debt (\$M): 1015.50 % Total Cap.: 12.20% Date: 12/13/2010

Share DataAuthorizedIssued% Total Cap.: 12.20%Preferred:0.000Common:398.100397.000Preferred Stock Dividend:Dilution: 1.100



- (1) Historical Sales Growth = 13.65%
- (2) Estimated Sales Growth = 8.00%

- (3) Historical EPS Growth = 21.54%
- (4) Estimated EPS Growth = 9.0%

ACE 5-year EPS Growth Estimate: 9.2%

Printed: 12/13/2010 7:09 PM Prepared by: ETANA Using The Stock Investment Guide by Churr Software

2 EVALUATING MANAGEMENT

STRYKER CORP (SYK) - 12/10/2010

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	5 Yr Ave	Trend
% Pretax Profit on Sales (Net Before Tax/Sales)	14.6	15.6	17.4	18.2	19.7	20.9	21.4	23.2	24.0	24.2	22.7	UP
% Earned on Invested Capital (EPS/Book Val)	25.2	24.9	23.3	20.8	20.9	21.8	19.6	18.3	20.7	17.8	19.6	DOWN
% Debt to Equity	102.6	68.1	32.8	0.9	0.0	5.7	0.0	0.0	0.0	0.0	1.1	DOWN

3 PRICE & EARNINGS HISTORY

Current Price: 53.08 52 Week High= 59.72

52 Week Low= 42.74

Year	High Price	Low Price	EPS	PE High	PE Low	Dividend	Payout	High Yield
2005	56.3	39.7	1.75	32.2	22.7	0.110	6.3	0.3
2006	55.9	39.8	2.02	27.7	19.7	0.220	10.9	0.6
2007	76.9	54.9	2.40	32.0	22.9	0.330	13.8	0.6
2008	74.9	35.4	2.83	26.5	12.5	0.400	14.1	1.1
2009	52.7	30.8	2.95	17.9	10.4	0.250	8.5	0.8
TOTAL	316.7	200.6						
AVE	63.3	40.1		27.3	17.6		10.7	
Average F	rice Earnings F	Ratio: 22.5	Current Price	e Earnings Rati	o: 16.5			

Current PE Ratio Based on Current EPS [\$3.22]

Projected PE Ratio of [15.1] Based on Projected EPS [\$3.5]

4 EVALUATING BUY, HOLD, & SELL

A. CALCULATED HIGH PRICE - 5 YEARS

Ave High PE 22.0 X Estimated High Earnings/Share 4.64 Projected High Price = \$ 102.1

B. CALCULATED LOW PRICE - 5 YEARS

(a) Avg. Low P/E 17.6 X Estimated Low Earnings/Share 2.95 = \$ 51.92

(b) Avg. Low Price of Last 5 Years = \$40.1 (e) Price Variant = \$37.8

(c) Recent Market Low = \$30.8 (d) Dividend Price Support = \$22.7

Selected Estimated Low Price \$ 37.8

C. BUY/HOLD/SELL ZONES

Selected High of \$102.10 minus Selected Low of \$37.80 = \$64.30 Range. 1/4 of Range = \$16.075

Lower 1/3 = \$37.8 To \$53.88 (Buy) **25%/50%/25% Zoning**

Center 1/3 = \$53.88 To \$86.03 (Hold)

Upper 1/3 = \$86.03 To \$102.1 (Sell)

D. UPSIDE RISK ANALYSIS

High Price 102.1 - Current Price 53.08 = 3.2 to 1 Current price of \$53.08 is in the BUY zone

Current Price <u>53.08</u> - Low Price <u>37.8</u> PEG Ratio = 1.83 Relative Value = 73.3% Proj PEG = 1.68 Proj Rel Value = 67.2%


5 YIELD ANALYSIS


Current Yield = (100 * Current Dividend)÷Current Price = 100 * 0.60 / 53.1 = 1.1%Ave. 5 Yr. Yield = (Ave. EPS(5Yr) * Ave. Payout)÷Current Price = (3.82 * 10.7)/53.1 = 0.8%

Price Appreciation = ((100*Projected High Price*Current Price)-100)÷5 = 18.5 % P.A.R Tot. Ret.

Average Total Return = Price Appreciation+Ave. 5 Yr. Yield = 19.3 % Average Yield 0.5% 0.5% Annual Appreciation 11.6% 14.0%

Compounded Annual Return 12.1% 14.5%





Quarterly Performance

Trailing Twelve Months

Quarterly Performance

	SALES		P	PRETAX PROFIT			EARNINGS		
Period	\$ mil	% Chg	\$ mil	% Sales	% Chg	\$	% Chg		
9-10	1767.6	6.9%	437.6	24.8%	14.7%	0.80	15.9%		
6-10	1758.2	7.6%	442.6	25.2%	10.6%	0.80	9.6%		
3-10	1799.1	12.4%	445.8	24.8%	15.4%	0.80	12.7%		
12-09	1834.2	6.8%	460.6	25.1%	11.0%	0.82	10.8%		
9-09	1653.3	0.0%	381.4	23.1%	1.4%	0.69	4.5%		
6-09	1634.3	-4.6%	400.0	24.5%	-4.8%	0.73	0.0%		
3-09	1601.3	-2.0%	386.4	24.1%	-4.4%	0.71	1.4%		
12-08	1718.2	3.6%	415.0	24.2%	8.1%	0.74	12.1%		
9-08	1653.0	13.7%	376.0	22.7%	18.3%	0.66	20.0%		
6-08	1712.6	17.0%	420.1	24.5%	19.5%	0.73	19.7%		
3-08	1634.4	14.7%	404.0	24.7%	20.1%	0.70	18.6%		
12-07	1658.1	18.4%	384.0	23.2%	21.7%	0.66	20.0%		
9-07	1453.2	18.0%	317.9	21.9%	22.2%	0.55	22.2%		
6-07	1463.7	16.0%	351.6	24.0%	19.7%	0.61	17.3%		
3-07	1425.5	13.7%	336.4	23.6%	21.5%	0.59	20.4%		
12-06	1400.4	9.5%	315.6	22.5%	17.3%	0.55	19.6%		

Trailing Twelve Months

	SALES				PERC	ENT CHAI	NGE
Period	\$ mil	\$ mil	% Sales	\$	Sales	PTP	EPS
9-10	7159.1	1786.6	25.0%	3.22	8.4%	12.9%	12.2%
6-10	7044.8	1730.4	24.6%	3.11	6.6%	9.7%	9.5%
3-10	6920.9	1687.8	24.4%	3.04	3.5%	5.7%	7.0%
12-09	6723.1	1628.4	24.2%	2.95	0.1%	0.8%	4.2%
9-09	6607.1	1582.8	24.0%	2.87	-0.8%	-0.1%	4.4%
6-09	6606.8	1577.4	23.9%	2.84	2.3%	3.4%	7.6%
3-09	6685.1	1597.5	23.9%	2.84	7.7%	9.6%	12.7%
12-08	6718.2	1615.1	24.0%	2.83	12.0%	16.2%	17.4%
9-08	6658.1	1584.1	23.8%	2.75	15.9%	19.9%	19.6%
6-08	6458.3	1526.0	23.6%	2.64	17.0%	20.7%	20.0%
3-08	6209.4	1457.5	23.5%	2.52	16.7%	20.9%	19.4%
12-07	6000.5	1389.9	23.2%	2.41	16.6%	21.2%	19.9%
9-07	5742.8	1321.5	23.0%	2.30			
6-07	5520.7	1263.8	22.9%	2.20			
3-07	5318.8	1206.0	22.7%	2.11			
12-06	5147.2	1146.5	22.3%	2.01			



